Comparison of Peripheral Low Dose with or without Flattening Filter in SABR and VMAT

碩士 === 高雄醫學大學 === 醫學影像暨放射科學系碩士在職專班 === 104 === Purpose: To investigate the flattening filter free (FFF) photon beam properties and assessing the impact of peripheral low dose in current mainstream radiotherapy in VMAT and SABR. Materials and Methods: In the same quality of treatment plans, we compar...

Full description

Bibliographic Details
Main Authors: Wei-Lin Chen, 陳韋霖
Other Authors: Pao-Shu Chang
Format: Others
Language:zh-TW
Published: 2016
Online Access:http://ndltd.ncl.edu.tw/handle/97193939822510780825
id ndltd-TW-104KMC05770034
record_format oai_dc
spelling ndltd-TW-104KMC057700342017-07-30T04:41:27Z http://ndltd.ncl.edu.tw/handle/97193939822510780825 Comparison of Peripheral Low Dose with or without Flattening Filter in SABR and VMAT 比較一般射束及高強度射束之周邊低劑量於立體定位消融性放射治療和旋弧調控放射治療 Wei-Lin Chen 陳韋霖 碩士 高雄醫學大學 醫學影像暨放射科學系碩士在職專班 104 Purpose: To investigate the flattening filter free (FFF) photon beam properties and assessing the impact of peripheral low dose in current mainstream radiotherapy in VMAT and SABR. Materials and Methods: In the same quality of treatment plans, we compare the convention and FFF beam modes, respectively. The T1 phase non-small cell lung cacer (NSCLC) treatment by stereotactic ablative radiotherapy (SABR) and the pediatric glioma treat by volumetric modulated arc therapy (VMAT), using optically stimulated luminescence dosimetry (OSLD) and anthropomorphic Rando phantom, measurement the out of field dose of normal tissues. Results: The NSCLC T1 phase treat by SABR FFF beam mode, total prescription dose was 60 Gy, peripheral dose including the lens, thyroid, apex, lung, esophagus, heart, lower lung, breast, liver, stomach, kidney, ascending colon, descending colon, ovarian and bladder show an average reduction was 27.03%, 8.23%, 14.11%, 17.40%, 17.85 %, 13.00%, 20.09%, 21.69%, 25.28%, 23.62%, 23.99%, 36.71%, 27.11%, 57.71% and 40.52% , respectively. The pediatric glioma treat by VMAT FFF beam mode, total prescription dose was 54 Gy, peripheral dose including the thyroid, apex, esophagus, heart, lung, breast, liver, kidney, intestine, ovarian and bladder show an average reduction was 22.64%, 27.20%, 21.33%, 22.78%, 22.36%, 22.35%, 24.25%, 22.54%, 31.10%, 46.98% and 45.76%, respectively. Compared to conventional beam, all the average absorbed dose of surrounding organs was lower when treat by FFF beam mode. Conclusion: Comparing with flattening filter beam and FFF beam, results showed that FFF beam decrease peripheral dose and reduced the risks of the radiation induced secondary malignancies, more obvious at 10 cm distance from field size edge and average reduces 47% (MAX), 32% (SABR) and 28% (VMAT). It need to be consider in patients with longer survival life after radiation therapy or pediatric patients. Pao-Shu Chang 張寶樹 2016 學位論文 ; thesis 89 zh-TW
collection NDLTD
language zh-TW
format Others
sources NDLTD
description 碩士 === 高雄醫學大學 === 醫學影像暨放射科學系碩士在職專班 === 104 === Purpose: To investigate the flattening filter free (FFF) photon beam properties and assessing the impact of peripheral low dose in current mainstream radiotherapy in VMAT and SABR. Materials and Methods: In the same quality of treatment plans, we compare the convention and FFF beam modes, respectively. The T1 phase non-small cell lung cacer (NSCLC) treatment by stereotactic ablative radiotherapy (SABR) and the pediatric glioma treat by volumetric modulated arc therapy (VMAT), using optically stimulated luminescence dosimetry (OSLD) and anthropomorphic Rando phantom, measurement the out of field dose of normal tissues. Results: The NSCLC T1 phase treat by SABR FFF beam mode, total prescription dose was 60 Gy, peripheral dose including the lens, thyroid, apex, lung, esophagus, heart, lower lung, breast, liver, stomach, kidney, ascending colon, descending colon, ovarian and bladder show an average reduction was 27.03%, 8.23%, 14.11%, 17.40%, 17.85 %, 13.00%, 20.09%, 21.69%, 25.28%, 23.62%, 23.99%, 36.71%, 27.11%, 57.71% and 40.52% , respectively. The pediatric glioma treat by VMAT FFF beam mode, total prescription dose was 54 Gy, peripheral dose including the thyroid, apex, esophagus, heart, lung, breast, liver, kidney, intestine, ovarian and bladder show an average reduction was 22.64%, 27.20%, 21.33%, 22.78%, 22.36%, 22.35%, 24.25%, 22.54%, 31.10%, 46.98% and 45.76%, respectively. Compared to conventional beam, all the average absorbed dose of surrounding organs was lower when treat by FFF beam mode. Conclusion: Comparing with flattening filter beam and FFF beam, results showed that FFF beam decrease peripheral dose and reduced the risks of the radiation induced secondary malignancies, more obvious at 10 cm distance from field size edge and average reduces 47% (MAX), 32% (SABR) and 28% (VMAT). It need to be consider in patients with longer survival life after radiation therapy or pediatric patients.
author2 Pao-Shu Chang
author_facet Pao-Shu Chang
Wei-Lin Chen
陳韋霖
author Wei-Lin Chen
陳韋霖
spellingShingle Wei-Lin Chen
陳韋霖
Comparison of Peripheral Low Dose with or without Flattening Filter in SABR and VMAT
author_sort Wei-Lin Chen
title Comparison of Peripheral Low Dose with or without Flattening Filter in SABR and VMAT
title_short Comparison of Peripheral Low Dose with or without Flattening Filter in SABR and VMAT
title_full Comparison of Peripheral Low Dose with or without Flattening Filter in SABR and VMAT
title_fullStr Comparison of Peripheral Low Dose with or without Flattening Filter in SABR and VMAT
title_full_unstemmed Comparison of Peripheral Low Dose with or without Flattening Filter in SABR and VMAT
title_sort comparison of peripheral low dose with or without flattening filter in sabr and vmat
publishDate 2016
url http://ndltd.ncl.edu.tw/handle/97193939822510780825
work_keys_str_mv AT weilinchen comparisonofperipherallowdosewithorwithoutflatteningfilterinsabrandvmat
AT chénwéilín comparisonofperipherallowdosewithorwithoutflatteningfilterinsabrandvmat
AT weilinchen bǐjiàoyībānshèshùjígāoqiángdùshèshùzhīzhōubiāndījìliàngyúlìtǐdìngwèixiāoróngxìngfàngshèzhìliáohéxuánhúdiàokòngfàngshèzhìliáo
AT chénwéilín bǐjiàoyībānshèshùjígāoqiángdùshèshùzhīzhōubiāndījìliàngyúlìtǐdìngwèixiāoróngxìngfàngshèzhìliáohéxuánhúdiàokòngfàngshèzhìliáo
_version_ 1718509353745514496